Alzamend is a clinical-stage biopharmaceutical company developing therapies for Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and PTSD. Alzamend has no approved products and generates no revenue, operating a binary business model that depends on advancing drug candidates through clinical trials toward FDA approval. Alzamend plans to partner with established pharmaceutical firms for late-stage development and marketing or pursue an outright sale of its programs. Its lead candidate, AL001, is a novel lithium formulation designed to deliver therapeutic levels to the brain at lower systemic doses than standard treatments. Alzamend argues this reformulation could eliminate the requirement for routine blood monitoring, making lithium safer for fragile patients. AL001 utilizes the Section 505(b)(2) regulatory pathway, which allows the company to rely on existing safety data for approved lithium salts. ALZN002 is an autologous cell-based vaccine that uses a patient's own immune cells to target and clear amyloid plaques. While AL001 is in Phase II trials, ALZN002 remains on clinical hold until the company engages a replacement contract research organization (CRO). Alzamend maintains a lean operational structure by relying on consultants and third-party contractors for research and manufacturing.